| Sular Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Sular 10 mg | tablet, extended release | oral | 1.0 each | OTC |
| Sular 30 mg | tablet, extended release | oral | 1.0 each | OTC |
| Sular 20 mg | tablet, extended release | oral | 1.0 each | OTC |
| Sular 40 mg | tablet, extended release | oral | 1.0 each | OTC |
Posted by iowamom about 1 year ago
Developed hot flushes that were unbearable...followed by such severe headaches that I literally could not move. Sat dead stil...
Posted by pgilbert over 2 years ago
I have been on Sular 2 weeks. I have experienced headaches, nasal congestion, rapid heart rate on exertion, leg cramps, and s...
Posted by midnight over 2 years ago
i had a stroke two weeks after taking med. i am only 42
Wet Seal Chief Operating Officer, Gary White To Step Down - Update - RTT News
Sciele recorded pre-tax restructuring and Sular related charges of $8.9 million or $0.21 per share in the fourth quarter of 2007, related to the launch of ...
Tue Feb 26 17:37:58 -0500 2008
BUYINS.NET: (SCRX) SqueezeTrigger Price is $22.027. There is ... - Trading Markets (press release)
In March 2002, it acquired rights to distribute and sell the antihypertensive prescription medication Sular from AstraZeneca and Bayer Healthcare in the ...
Wed Feb 27 04:44:52 -0500 2008
Wet Seal Chief Operating Officer, Gary White To Step Down - Update - RTT News
Sciele recorded pre-tax restructuring and Sular related charges of $8.9 million or $0.21 per share in the fourth quarter of 2007, related to the launch of ...
Tue Feb 26 17:37:58 -0500 2008
nisoldipine - A dihydropyridine calcium channel blocking agent. Nisoldipine inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility. This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)